相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII
Krishna Gundabolu et al.
HAEMOPHILIA (2020)
Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
Patrick T. Ebbert et al.
HAEMOPHILIA (2020)
Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring
Christine Biron-Andreani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement
Elena Santagostino et al.
HAEMATOLOGICA (2019)
Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors
Donald F. Brophy et al.
HAEMOPHILIA (2019)
Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays
Joanne Adamkewicz et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis
Koji Yada et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Emicizumab and thrombosis: The story so far
Michael Makris et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort
Assaf A. Barg et al.
PEDIATRIC BLOOD & CANCER (2019)
Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A
Jens Mueller et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Steven W. Pipe et al.
LANCET HAEMATOLOGY (2019)
Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis
Glaivy Batsuli et al.
HAEMOPHILIA (2019)
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
Midori Shima et al.
HAEMOPHILIA (2019)
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Guy Young et al.
BLOOD (2019)
Emicizumab use in major orthopedic surgery
Craig D. Seaman et al.
BLOOD ADVANCES (2019)
Deep vein thrombosis in pediatric patients
Julie Jaffray et al.
PEDIATRIC BLOOD & CANCER (2018)
International Study of the Epidemiology of Paediatric Trauma: PAPSA Research Study
Catherine J. Bradshaw et al.
WORLD JOURNAL OF SURGERY (2018)
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab
Yesim Dargaud et al.
HAEMATOLOGICA (2018)
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab
Yesim Dargaud et al.
HAEMATOLOGICA (2018)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis
Karen L. Zimowski et al.
BLOOD (2018)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project
Marilyn J. Manco-Johnson et al.
BLOOD (2017)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Midori Shima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors
Elena Santagostino et al.
BLOOD REVIEWS (2015)
Toward optimal therapy for inhibitors in hemophilia
Christine L. Kempton et al.
BLOOD (2014)
Venous access in haemophilic children: choice and management
E. SANTAGOSTINO et al.
HAEMOPHILIA (2010)
The risk associated with indwelling catheters in children with haemophilia
Rolf Ljung
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT)
Harald Haidl et al.
THROMBOSIS AND HAEMOSTASIS (2006)
Calibrated automated thrombin generation measurement in clotting plasma
HC Hemker et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2003)